Prostate cancer drug now available to more patients with aggressive form of disease
A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease.Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food and Drug Administration (FDA) has expanded approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy (RLT) that is given before chemotherapy.(RLTs are a form of targeted nuclear medicine that doctors use to treat multiple types of […]